Everest Medicines Ltd
HKEX:1952
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.54
39.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Everest Medicines Ltd
Gross Profit
Everest Medicines Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Everest Medicines Ltd
HKEX:1952
|
Gross Profit
¥91.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Gross Profit
¥14.7B
|
CAGR 3-Years
108%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Gross Profit
¥4.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
335%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Gross Profit
¥4.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Gross Profit
¥3.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Gross Profit
¥9.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
34%
|
|
Everest Medicines Ltd
Glance View
Everest Medicines Ltd. operates as a biopharmaceutical company which focuses on licensing, clinical development and commercialization of globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company is headquartered in Shanghai, Shanghai and currently employs 405 full-time employees. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
See Also
What is Everest Medicines Ltd's Gross Profit?
Gross Profit
91.5m
CNY
Based on the financial report for Dec 31, 2023, Everest Medicines Ltd's Gross Profit amounts to 91.5m CNY.
What is Everest Medicines Ltd's Gross Profit growth rate?
Gross Profit CAGR 1Y
1 023%
Over the last year, the Gross Profit growth was 1 023%.
You don't have any saved screeners yet
